HKeyBio Launches AI-NAM-Bridge™ to Streamline Preclinical Drug Development
Event summary
- HKeyBio introduced HKEY-AI-NAM-Bridge™ 1.0 on July 13, 2026, a service connecting AI predictions, New Approach Methodologies (NAMs), and in vivo evidence for autoimmune and allergy drug development.
- The package helps identify evidence gaps between AI predictions, in vitro systems, omics data, and disease-relevant in vivo models.
- Key deliverables include evidence gap assessments, minimal animal study designs, biomarker and PK/PD bridging plans, and NHP necessity assessments.
The big picture
HKeyBio's launch of HKEY-AI-NAM-Bridge™ reflects the broader industry shift toward leveraging AI and NAMs to enhance preclinical study design, reducing reliance on traditional animal testing while improving target validation. This aligns with regulatory trends favoring more efficient, data-driven approaches in drug development.
What we're watching
- Adoption Pace
- How quickly autoimmune and allergy drug developers will integrate HKeyBio's AI-NAM-Bridge™ into their preclinical workflows.
- Regulatory Acceptance
- Whether regulatory bodies will endorse the bridging of AI, NAMs, and in vivo evidence for IND-enabling studies.
- Competitive Differentiation
- The extent to which HKeyBio can maintain a competitive edge with this service amid growing AI-driven preclinical tools.
Related topics